CTCA doses first patient in groundbreaking immunotherapy clinical trial
Clinical investigators at Cancer Treatment Centers of America (CTCA) in Phoenix have dosed the first patient in the first-in-human study of NKTR-255, a first-in-class immunotherapy developed by Nektar Therapeutics. This Phase 1…